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Abstract 18 
Objective To assess the effectiveness of community-wide deployment of insecticide–19 
impregnated collars for dogs- the reservoir of Leishmania infantum – to reduce infantile 20 
clinical visceral leishmaniasis (VL). 21 
Methods A pair matched–cluster randomised controlled trial involving 40 collared and 40 22 
uncollared control villages (161 [95% C.L.s: 136, 187] children per cluster), was designed to 23 
detect a 55% reduction in 48 month confirmed VL case incidence. The intervention study was 24 
designed by the authors, but implemented by the Leishmaniasis Control Program in NW Iran, 25 
from 2002 to 2006. 26 
Results The collars provided 50% (95% C.I. 17·8%–70·0%) protection against infantile VL 27 
incidence (0·95/1000/yr compared to 1·75/1000/yr). Reductions in incidence were observed 28 
 2 
across 76% (22/29) of collared villages compared to pair–matched control villages, with 31 29 
fewer cases by the end of the trial period. In 11 paired villages, no further cases were 30 
recorded post–intervention, whereas in 7 collared villages there were 9 new clinical cases 31 
relative to controls. Over the trial period, 6,835 collars were fitted at the beginning of the 4 32 
month sand fly season, of which 6.9% (95% C.I. 6.25%, 7.56%) were lost but rapidly 33 
replaced. Collar coverage (percent dogs collared) per village varied between 66% and 100%, 34 
with a mean annual coverage of 87% (95% C.I. 84·2, 89·0%). The variation in post-35 
intervention clinical VL incidence was not associated with collar coverage, dog population 36 
size, implementation logistics, dog owner compliance, or other demographic variables tested. 37 
Larger reductions and greater persistence in incident case numbers (indicative of 38 
transmission) were observed in villages with higher pre-existing VL case incidence.    39 
 40 
Conclusion Community–wide deployment of collars can provide a significant level of 41 
protection against infantile clinical VL, achieved in this study by the local VL Control 42 
Program, demonstrated attributes desirable of a sustainable public health program. The 43 
effectiveness is not dissimilar to the community-level protection provided against human and 44 
canine infection with L. infantum. 45 
 46 
Author summary 47 
Zoonotic visceral leishmaniasis is a sand fly-borne disease of humans and dogs caused by the 48 
intracellular parasite Leishmania infantum. Dogs are the proven reservoir. The disease is of 49 
global health significance, and usually fatal unless treated. There are limited options to reduce 50 
transmission. Insecticide-treated dog collars have been shown to protect dogs against 51 
infectious bites from sand fly vectors, resulting in reductions of new infections in both dogs 52 
and humans. However, there have been no studies to demonstrate the public health benefits of 53 
this approach i.e. the impact on clinical VL incidence. This study assessed the effectiveness 54 
of community-wide deployment of insecticide–impregnated collars on dogs to reduce the 55 
incidence of clinical visceral leishmaniasis in children, the high risk age-group. Collars were 56 
 3 
fitted to dogs in 40 endemic villages over 4 consecutive years by the regional public health 57 
authorities in NW Iran. The case incidence of infantile visceral leishmaniasis in these villages 58 
was compared to that in 40 untreated villages at the end of the intervention period. The 59 
community-wide deployment of collars proved to provide a 50% reduction in the 60 
development of the disease in children. This effect was achieved under the operational 61 
conditions of the regional routine health authorities. We conclude that the implementation of 62 
insecticide-impregnated collars be considered in strategic scale-up operations against 63 
zoonotic visceral leishmaniasis.  64 
 65 
Introduction 66 
Visceral leishmaniasis (VL) is a protozoan vector–borne parasitic disease of humans 67 
following infection with Leishmania donovani or L. infantum, characterized by prolonged 68 
fever, wasting, splenomegaly, and hepatomegaly, and >95% case–fatality in the absence of 69 
treatment[1]. Leishmania are transmitted by female Phlebotomine sand flies. Leishmaniasis is 70 
a Neglected Tropical Disease (NTD) strongly associated with poverty and malnutrition[2], 71 
resulting in a global incidence of 50,000 to 90,000 new VL cases per year[1]. Difficulties in 72 
reducing VL case burdens arise due to the current lack of a human vaccine, limited safe 73 
therapeutic drugs, need for improved vector control, and a better understanding of 74 
transmission dynamics[3-5]. 75 
 76 
VL due to L. donovani is anthroponotically transmitted, whereas VL due to L. infantum is a 77 
zoonosis involving infectious domestic dog reservoirs[6], and uncertain role of humans[7], in 78 
maintaining transmission[8]. Otherwise traditionally known as “infantile VL”, zoonotic VL is 79 
a disease mainly of young children[9-14], although case age-distributions may vary e.g. [15, 80 
16].  81 
 82 
Regional VL control programs focus on human case detection and treatment, adult sand fly 83 
vector control, and for dogs, optional strategies including canine vaccination, topical 84 
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insecticide protection, chemotherapeutic treatment, or euthanasia[17-19]. Anthroponotic VL 85 
has been targeted for elimination as a public health problem (<1 case/10,000 people per year 86 
at district levels) in the Indian subcontinent by 2020, with substantial investment, technical 87 
and political support[3, 5, 20]. This has contributed to significant reductions in incidence 88 
between 2012 and 2017 [1, 12, 21]. In contrast, investment to reduce zoonotic VL in endemic 89 
Latin America, central Asia and Caucasia, are minimal by comparison; no such reductions in 90 
incidence are observed notably in the Americas where >90% of cases occur [22, 23].  91 
 92 
Vector and animal reservoir control are necessary to reduce zoonotic VL incidence as 93 
treatment of human clinical cases, though necessary, is unlikely to impact on the transmission 94 
cycle. Insecticides topically applied to dogs as slow release insecticide–impregnated collars 95 
have been extensively tested in different regions, showing that they are effective against sand 96 
fly vectors[24-28], and reduce infection risk in dogs[29-37]. Evidence that collars also can 97 
reduce human infection incidence is limited to a single cluster randomized trial conducted in 98 
NW Iran[31]. However, there are no peer-reviewed studies to test the impact of this approach 99 
on human clinical VL disease. 100 
 101 
In collaboration with the regional VL control program authorities in NW Iran, and with 102 
access to VL case records provided by the Ministry of Health (MoH), we had the opportunity 103 
to evaluate the impact of community–wide distribution of collars against clinical VL 104 
incidence, and as conducted under operational conditions. The principal aims of the study 105 
were (i) to measure the efficacy of the collar intervention against VL case incidence; (ii) to 106 
evaluate the operational logistics of collar implementation; and (iii) to assess likely causes for 107 
the variation in intervention effectiveness. 108 
 109 
Methods 110 
Study location   111 
The study was conducted in the rural	communities	of	the	Kalaybar and Ahar administrative 112 
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districts of East Azerbaijan province, NW Iran (38688131N;	4321696E)	from 2002 to 113 
2006. Villages	were	located	at	altitudes	of	369-1305m	(Table	1).	The	main	economic	114 activity	in	the	area	is	agriculture,	cash	crops	and	particularly	sheep	farming.	Dogs	are	115 kept	as	shepherd	dogs	or	household	guard	dogs,	and	small	numbers	of	livestock	(sheep,	116 goats,	cattle,	chickens)	are	kept	in	shelters	variably	near	or	attached	to	houses.	Houses	117 are	constructed	of	plastered	or	unplastered	stone,	cement,	or	brick,	and	rooves	118 constructed	of	cement,	thatched	or	corrugated	iron.	Dried	manure	is	generally	stocked	119 in	piles	away	from	houses	as	a	source	of	fertilizer	and	fuel.	Temperatures	ranged	from	120 10C	(in	January)	to	230C	(in	July/August),	and	rainfall	from	18mm	(in	August)	to	76mm	121 (in	May).		122 
 123 
In the region, 100–150 new VL cases were reported annually between 1998 and 2005, 124 
representing 45% of the total VL cases in Iran, the vast majority being children <10yrs of 125 
age[9-11, 38]. At the time of the study, pediatric L. infantum infection incidence measured by 126 
Direct Agglutination Test (DAT) seroconversion was 2·4% compared to 1.9% by Leishmanin 127 
skin test (LST) reaction [31]. Canine DAT seroconversion incidence was 7%[31], with 128 
reported regional seroprevalences of 11%-22% [31, 38, 39]. In the same locations, the canine 129 
to human seroprevalence ratio was 1.4: 1 (11% vs 8%)[31] compared to 3.1:1 (22% vs 7%) 130 
six years earlier in 1995[39]. Transmission is predominantly peridomestic, with human 131 
exposure being independent of age and sex, and associated with endophilic Phlebotomus sand 132 
fly vectors and infected dogs[39-43]. The	risk	of	childhood	Leishmania	seropositivity	is		133 associated	with	dog	ownership,	village	dog	density	(28/km2,	95%	C.I.:	23.6-32.1),	and	134 the	dog	to	human	ratio[39]. Two species of sand fly, Phlebotomus (Larroussius) perfiliewi 135 
transcaucasicus and Ph. (L.) kandelakii, are likely vectors in this region, being seasonally 136 
active for 4 months (late June to October)[41, 44].  137 
 138 
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The VL control program hinges on the District Ministry of Public Health (DTARH) which is 139 
responsible for the District Health Centers (DHCs) in Kalaybar and Ahar. These centers 140 
coordinate activities of 12 provincial Rural Health Centers (RHCs), which are run by trained 141 
medical staff and health officers. Each RHC supervises about ten village health posts (khaneh 142 
behdasht) where resident Health Promoters (behvarz) are responsible for disease surveillance, 143 
control implementation, and facilitate suspect VL cases attendance at the RHCs. The RHCs 144 
provide free VL diagnostic testing and treatment services, and refer those needing more 145 
specialist hospitalization to the DHCs or district hospital. Clinical VL is a notifiable disease. 146 
 147 
Study design 148 
Randomisation and treatment allocation  149 
The trial was designed as a pair–matched cluster randomised trial[45]. Villages were 150 
designated as clusters and selected in a two–step procedure (Figure 1). All 417 endemic 151 
villages in the two districts, and confirmed VL case numbers in the 4·5 years prior to the 152 
intervention (January 1998– June 2002) were listed. The inclusion criteria for village 153 
recruitment were that the population size was >100, at least one confirmed clinical VL case 154 
was recorded in this period, and that the village population was not nomadic. A total of 91 155 
villages met these criteria.  156 
 157 
Following consultation by the RHC supervisors with village leaders and health workers, 80 of 158 
the more accessible villages were finally recruited. Ranked in descending order of pre–159 
intervention VL incidence, the top two villages were paired and randomly assigned to the 160 
treatment (collars) or control (no collars) group by tossing a coin in the presence of observers. 161 
All subsequent pairs were similarly assigned alternately to either the treatment or control 162 
group, resulting in 40 control and 40 pair-matched villages.  163 
 164 
The pre–intervention DTARH house–to–house survey indicated that the collar and control 165 
villages (clusters) were demographically well balanced (Table 1). Although Iran has a 166 
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national Leishmania control program, during the trial period neither insecticide spraying, 167 
canine test–and–slaughter, nor VL health education programs were conducted in the enrolled 168 
communities. However, 27 stray dogs were removed by the authorities (11 and 16 dogs from 169 
five and seven control and collar villages, respectively).  170 
  171 
Table 1. Demographic characteristics of trial villages (clusters).  172 
 Collar arm Control arm   
Total numbers per arm     
Villages  40 40   
Human population 22904 22844   
Children 0–10 yrs 6341 6562   
Households 3760 4011   
Dogs 1962 1670   
Houses with ≥1 dog 1364 1387   
     
Geometric mean (95% 
C.L.s) per village   
Wilcoxon 
rank-sum 
z 
P£ 
Proportion of the population 
0–10 yrs 0·27 (0·256, 0·283) 0·29 (0·270, 0·301) 
1.29 0.190 
M : F sex ratio children 0–
15 yrs 0·99 (0·921, 0·106) 1·03 (0·978, 1·09) 
0.85 0.394 
Ratio shepherd: guard dog 
per village 0·45 (0·350, 0·589) 0·46 (0·344, 0·570) 
0.55 0.389 
Households per village 72 (56·4, 91·4) 82 (66·9, 100·8) 1.00 0.319 
Humans population per 
village 469 (383·3, 574·2) 478 (392·9, 580·4) 
0.20 0.840 
Children 0–10 yrs per 
village 126 (101·1, 157·7) 136 (112·0, 165·6) 
0.50 0.620 
Dogs per village 43 (36·5, 50·2) 37 (31·5, 43·6) 0.69 0.488 
Ratio dogs to children 0·34 (0·256, 0·449) 0·27 (0·209, 0·354) 0.20 0.229 
Proportion population 
literate 0·40 (0·356, 0·444) 0·48 (0·417, 0·545) 
1.40 0.088 
Proportion population 
employed 0·21 (0·189, 0·241) 0·27 (0·200, 0·258) 
0.83 0.408 
Proportion houses with dog 0·39 (0·300, 0·522) 0·35 (0·266, 0·467) 0.33 0.740 
Village altitude (m) 664 (544·4, 810·2) 674 (594·7, 763·5) 0.46 0.591 
Ratio dogs to human 0·09 (0·070, 0·118) 0·08 (0·059, 0·102) 1.09 0.275 
 173 
The Intervention 174 
Dog collars impregnated with 40mg/g deltamethrin (Scalibor® ProtectorBand, Intervet 175 
International, Boxmeer, Netherlands), were fitted to household dogs in the 40 treatment 176 
villages in late June/early July in each of four consecutive years (2002–2005). The Scalibor® 177 
collar label claimed 5-6 months insecticidal activity[25, 26] which exceeded the annual 178 
transmission season.  179 
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 180 
The intervention was implemented by DTARH operational DHCs in Kalaybar and Ahar. The 181 
collars were donated by Intervet, and given to the DHCs who distributed them to the village 182 
Health Promoters, ensuring that sufficient collars and replacements were supplied each year. 183 
Health Promoters conduct routine house–to–house visitation forming part of the DTARH 184 
public health advisory and monitoring system. On these visits, they fitted the collars to dogs, 185 
promoted the correct use of the collars, recorded the daily numbers of collars fitted, lost, 186 
replaced, or refusals to fit collars (defined here as non-compliance), and identified any 187 
adverse clinical effects reported by dog owners. The authors helped train the Health 188 
Promoters to systematically record these events.  189 
 190 
VL case definition and reporting 191 
Confirmed clinical VL case numbers were extracted from secondary records provided by 192 
DTARH. At the time of the study, the DTARH protocol stated that suspect VL cases were 193 
considered confirmed if they presented clinical signs including prolonged fever, 194 
lymphadenopathy, and hepatosplenomegaly, associated with a positive DAT (threshold 195 
³1/3200 titer), and/or microscopic detection of Leishmania in clinical aspirates. All 196 
confirmed cases received treatment following WHO guidelines[12]. Based on parasite 197 
infections found in sand flies(Parvizi, Mazloumi-Gavgani et al. 2008), Leishmania tropica is 198 
also transmitted in the region. However, this parasite typically causes cutaneous infections, 199 
does not normally induce DAT seroconversion, and the distinctive clinical signs are known 200 
by the DHCs.  201 
 202 
Data management and masking 203 
DTARH collated details of confirmed VL incident cases which were provided to the authors 204 
anonymised accompanied by records of the patient’s age, sex, village of residence, and date 205 
when they first presented at the medical center.  206 
Lacking placebo collars, the village Health Promotors were not blinded to the intervention, 207 
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but the clinicians and DTARH data managers who collated the case data were.  208 
 209 
Trial outcomes 210 
The primary outcome for analysis was the cumulative number of incident VL cases per 211 
village by the end of the 48 months follow–up period. The transmission season of infection 212 
was attributed based on the date of the patient’s initial presentation: dates falling between 213 
Julyyear ´ and end of Juneyear ´+1 were assigned to transmission seasonyear ´. This interval 214 
allowed for a ³9 month incubation period which exceeds the usual 2–6 months incubation 215 
period reported in Iran and elsewhere[38].  216 
 217 
Sample size calculations 218 
The study was statistically powered to detect a 55% reduction in the 48 month clinical VL 219 
incidence in collar clusters compared to control clusters, from baseline 0.004 (~3.978 cases 220 
per 1000 children ≤10yrs old/yr) calculated for the 4·5 yr pre–intervention period in the 80 221 
trial clusters, and a surveyed harmonic mean of 106 children per cluster. Data from the 222 
previous collar trial in the region[31], gave an inter–cluster coefficient of variation of κ = 223 
0·124 indicative of the degree of cluster pairwise matching achievable. We applied a more 224 
conservative κ = 0·25 in power calculations. Under these assumptions, 38 clusters per arm 225 
were required to achieve a power of 90% with α=0·05 to reject the null hypothesis. The final 226 
number of clusters enrolled was 40 clusters per arm. Comparison of unpublished DTARH 227 
and published[39] demographic records showed that the village humans and dog populations 228 
were generally stationary and stable.  229 
 230 
Statistical analysis 231 
The intervention effect was computed using random–effects Poisson regression to test 232 
differences in the cumulative numbers of incident VL cases per cluster (=village), expressed 233 
as an incidence risk ratio (IRR). The model included variables describing the trial design: the 234 
attributed year of infection, the log10 transformed childhood baseline village incidence, and 235 
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the pair–matching structure (as a cluster term). The number of children ≤10yrs per village, 236 
being the well documented high risk group, was set as the model offset parameter. The 237 
variance in cluster ratios of children to total population size were similar between treatment 238 
arms (Table 1). Additional demographic variables, listed in Table 1, were then individually 239 
tested by log–likelihood ratio test [LRT] of nested models, as potential modifiers of the 240 
unadjusted intervention effect estimates.  241 
 242 
A secondary analysis following[45] tested the normalized residuals of the observed /expected 243 
case ratios for pair-matched clusters (Supplementary S1), where the	expected	number	of	244 cases	per	cluster	were	generated	first	by	fitting	the	Poission	model,	simultaneously	245 adjusting	for	significant	covariates	as	described	above,	but	excluding	the	intervention	246 term.	Then,	normalized	(square	root	transformed)	residuals	of	the	observed	/expected	247 case	ratios	were	tested	by	Student’s	paired	t-test	where	the	results	of	each	cluster	are	248 given	equal	weighting[45]. Differences in these ratios were also confirmed by applying a 249 
non–parametric two–sided weighted signed rank test.  250 
 251 
The relationship between post-intervention VL incidence differences between pair-matched 252 
villages, and pre-intervention incidence, was examined by linear regression (illustrated in 253 
Figure 4). The relationships between village incidence pre– and post– intervention was 254 
evaluated by negative binomial regression (nbreg), and by Spearman’s rank correlation 255 
(illustrated in Figure 5).  256 
Data were analysed in Stata v.15.1 (StataCorp LP, College Station, TX). 257 
 258 
Ethical considerations 259 
The trial protocol was approved by the Regional Committee of Medical Ethics, Tabriz 260 
University of Medical Sciences, Iran. The University of Warwick’s Biomedical and Scientific 261 
Research Ethics Committee (BSREC) confirmed that the trial raised no significant ethical 262 
concerns due to its use of secondary anonymised human case data. There was no local animal 263 
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ethical committee at the time of the study.	Informed written consent was obtained from 264 
village leaders, and from dog owners to fit collars, and dogs were monitored on a regular 265 
basis by village Health Promotors for any adverse reactions to the collars.  266 
 267 
RESULTS 268 
In the 4·5 years prior to the intervention (January 1998– June 2002), 113 confirmed clinical 269 
VL cases were reported in a population of 6,562 children in the 40 control villages, with an 270 
average annual case incidence of 3·83 per 1000. In the 40 collar villages during the same 271 
period, 118 cases were recorded amongst 6,341 children, an average incidence of 4·14 per 272 
1000. These rates were not significantly different (IRR=1·04 [95% C.L.s 0·802, 1·344], 273 
p>0·77). 274 
 275 
During the 48 month intervention period, 24 compared to 46 clinical VL cases were recorded 276 
in the collar and control arms, respectively. The corresponding incidences were 0·95/1000/yr 277 
and 1·75/1000/yr. Accounting for a general decline in VL case numbers over the years of 278 
observation in both trial arms (Figure 2), there was a significant cumulative protective effect 279 
attributed to the collar intervention (LR test: χ2(1) =7·83, p=0·0051). The trial design–adjusted 280 
incidence risk ratio (IRR) was 0·50 (95% C.I. 0·300, 0·822) (model fit: Wald χ2(5) =25·7, 281 
p<0·0001), equivalent to 50% (95% C.I. 17·8%, 70·0%) protection against clinical VL.  282 
 283 
The intervention effect was further confirmed by showing a significantly lower than expected 284 
number of cases in collared vs control villages (Student’s t= -3.39, df=39, p=0·0016) 285 
(Supplementary S1). The non–parametric sign rank test of these residuals was also significant 286 
(p=0·008).  287 
 288 
Additional demographic variables (listed in Table 1) were individually tested for effect 289 
estimate modification, but none of the variables significantly improved the model fit (LRT: 290 
c2(1) <1·92, p>0·187).  291 
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 292 
VL case characteristics 293 
The median age of the 70 reported clinical cases during the trial period was 1.6yrs (range: 294 
0.5–5yrs), with M:F sex ratios of 25:21 and 12:12 in control and collar arms, respectively. 295 
There were no significant differences in case age distributions between trial arms (Poisson 296 
regression: z= -0·97, P=0·331), nor between intervention years (non–parametric test for 297 
trend: z= -1·54, p=0·124).  298 
 299 
Heterogeneities in the intervention effect 300 
Year of intervention 301 
The annual point estimates of the intervention effect suggested that the protective effect 302 
steadily increased with time under intervention, though the case numbers were low and the 303 
errors broad (Table 2). 304 
 305 
Table 2. Crude and adjusted clinical VL incidence risk ratios (IRR), and observed number of 306 
confirmed VL cases, per year under intervention.  307 
Year of 
intervention 
IRR (95% CLs) 
adjusted for trial design 
characteristics1 
 
IRR (95% CLs) unadjusted 
for trial design 
characteristics2 
VL cases (number 
in  collar/control 
arm)3 
2002 0·69 (0·31, 1·57) 0·74 (0·33, 1·66) 10/14 
2003 0·51 (0·23, 1·16)  0·55 (0·24, 1·23) 9/17 
2004 0·19 (0·06, 0·67)  0·21 (0·06, 0·71) 3/15 
2005 – – 2/0 
Average across 
2002–2005  
0·50 (0·30, 0·82) 
  
0·54 (0·33, 0·88) 24/46 
1 computed by fitting the RE Poisson model adjusted for trial design characteristics 308 
2 computed from analysis of the raw annual risk ratios in absence of trial design 309 
characteristics 310 
3 observed number of confirmed VL cases 311 
 312 
Variation in the intervention effect between villages 313 
By the end of the intervention, 12 (30%) of the 40 collar villages, compared to 24 (60%) of 314 
the 40 control villages, presented ³1 clinical VL case, indicating a reduced risk also at the 315 
village level (IRR=0·57 [95% C.I.s 0·372, 0·879],  c2(1) =7·27, p=0·007). 316 
 317 
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Eleven of the 40 paired–matched villages reported zero cases post–intervention in both 318 
treatment arms. Of the remaining 29 pairs, 22 (76%) collared villages showed reductions in 319 
incidence compared to the pair-matched control villages (Figure 3), with 11 new VL cases 320 
recorded compared to 42 VL cases in the control villages. However, in seven collared 321 
villages, there was an increase in incidence, with 13 VL cases compared to 4 cases in the 322 
pair-matched control villages over the 4 year period. 323 
 324 
The difference in post-intervention VL incidence between pair-matched villages attributed to 325 
the intervention was negatively associated with their pre-intervention baseline incidence 326 
(linear regression b= -0·427, z= -3·19, p<0.001) (Figure 4). This suggested that despite the 327 
general decline in VL case numbers by the end of the study, the intervention had a larger 328 
impact on higher compared to lower levels of pre-existing transmission intensity. 329 
 330 
In the control arm, there was a positive association between village pre– and post– 331 
intervention incidence (nbreg: b=0·095, z=1·86, p=0·06; Spearman’s r=0·420, p=0·007) 332 
(Figure 5). This relationship was interrupted by the intervention (nbreg: b= -0·107, z= -0·75, 333 
p=0·45; Spearman’s r= -0·109, p=0·50) (Figure 5). 334 
 335 
Collar coverage 336 
Over the trial period, 6,835 dogs were fitted with collars before the beginning of the sand fly 337 
season (1,682, 1,722, 1,689, and 1,742 dogs annually in the 4 years). Of these, 6.9% (95% 338 
C.I. 6.25%, 7.56%) were lost per year, respectively 7·3% (123/1,682), 6.4% (110/1722), 339 
6.9% (117/1689) and 7.0% (122/1742). The mean annual coverage (percent of total dogs 340 
collared) was 87% (95% C.I. 84·2, 89·0%) being consistent across years (Kruskal–Wallis 341 
test: c2(3) =0·260, p=0·967), although it varied significantly between villages (range: 65·7%–342 
100%) (Kruskal–Wallis test: c2(39) =0·122, p=0·0001) (Figure 6). Coverage in any single 343 
village and year was not associated with the village dog population size (z=1·14, p=0·26).  344 
 345 
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The variation in post-intervention VL incidence between pair-matched villages were not 346 
associated with the mean or variance in village collar coverage (t<0.67, p>0.51, r2 = 0.008); 347 
similar coverage was observed in villages with no incident VL cases, as those with >0 348 
incident VL cases (Figure 6).  349 
 350 
Intervention logistics 351 
Collar fitting, loss and replacement rates 352 
Based on the most complete daily records (2002 data), collars were distributed by the DHCs 353 
to all village Health Promoters within 16 days at the start of the study. Aligned from the date 354 
(19th June 2002) of supply to the first village, all collars were fitted in the 40 villages within 355 
one month.  356 
 357 
In individual villages, all collars were fitted within a median 14 days (IQR 12.3–14.0; range: 358 
4–30 days) from collar provision, with >70% in place within eight days. The number of dogs 359 
per village did not influence either the total fitting time (quantile regression: t=0·95, p=0·348) 360 
or daily fitting rates (comparison of daily slope interactions: z<0·71, p>0·54). Fitting rates	361 were	similar	for	guard	and	shepherd	dogs	(Two-sample	Wilcoxon	rank-sum	test:	z=-362 0.262,	p=0.794). 363 
 364 
Collars were lost in 35 of the 40 collar villages, 2–147 days post-fitting. A median 3 (IQR 2-365 
4; range 1–10) collars were lost per village. However, these were rapidly replaced: 59% 366 
within 4 days, and 91% within 8 days. 367 
 368 
Discussion 369 
The effectiveness of insecticide–impregnated collars against human clinical VL had not been 370 
trialled as a potential public health control option. Community–wide collar coverage over 4 371 
transmission seasons reduced the relative risk of infantile VL by 50% (95% C.I. 30%, 82%), 372 
and reduced the total VL case numbers by 48% during the intervention period.  373 
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 374 
The protective effect was clear despite a 70% general decline in reported case numbers over 375 
the study period, the decline being consistent with national trends from the late 1990s to 2014 376 
in Iran[9] and elsewhere: waxing and waning cycles in incident case numbers are reported in 377 
the Indian subcontinent[5], with speculation over the regulating mechanisms[46]. In Iran, VL 378 
is a notifiable disease, subject of major public health programs, and well known to physicians 379 
in the study region. Development of VL from subclinical infection in the region is 8% (1 in 380 
13 infections), where conversion risk declines with age associated with a rise in cell–381 
mediated immunity[40]. The observed VL cases were £5yrs old, similar to the VL age–382 
distributions throughout Iran[9-11]. This contrasts to the older average age groups afflicted 383 
with VL due to L. donovani infection[47], and in immunocompromised VL patients 384 
generally[16]. Traditionally a disease of children, variability in L. infantum VL case age 385 
distributions are appearing[23].  386 
 387 
All eight published studies designed to evaluate the efficacy of ScaliborÒ collars, 388 
demomstrated reduced canine seroinfection incidence by 46%–86% within 1–2 years of 389 
use[30-35, 37, 48]. They have been shown to reduce also sand fly densities[27], and sand fly 390 
infection prevalence with L. infantum[48]. The DTARH program did not monitor changes in 391 
canine infection rates or sand fly densities during the trial period, which is one limitation of 392 
this study. However, a previous cluster randomized trial of community-wide distribution of 393 
ScaliborÒ collars in the study region, reported protective effects against canine infection of 394 
54% [95% C.L.s 30%, 70%]), associated with a reduction in infection (cf. clinical disease) 395 
incidence of 43% (95% C.L. 10%, 63%) in ≤10yr old children[31]. What was not clear from 396 
that study, was whether reductions in seroconversion would directly translate into reductions 397 
in clinical VL incidence. ScaliborÒ collars release deltamethrin into dermal secretions, 398 
resulting in reduced sand fly blood–feeding by >90%, and increased mortality in blood–fed 399 
sand flies by 35%–100% over 8 months[25, 26]. More recent studies suggest that ScaliborÒ 400 
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collars offer 94-98% protection against Phlebotomous perniciosus sand fly bites for up to 12 401 
months[49]. These effects reduce the likelihood of a collared dog acquiring infection and 402 
being a source for onward transmission, thus, they are expected to reduce the number of 403 
infectious bites on humans. The risk of clinical development is associated with elevated 404 
parasite burdens and immune responses[50, 51]; collars may also reduce the metacyclic 405 
inoculum delivered by vectors, and/or the initial amastigote infection burdens, sufficient to 406 
reduce the subclinical to clinical VL conversion rate. Lower incident anti–Leishmania 407 
antibody titers, observed in seronegative collared dogs[32], support this hypothesis. 408 
 409 
The annual effect estimates in this study suggest that one to two years of continued 410 
intervention achieved a similar outcome to the 4-year cumulative effect. However, the point 411 
estimate errors were broad as the study was not statistically powered to detect significant 412 
changes in any single transmission season. Interpretation of the effect estimates over time 413 
was further hindered by the very low VL case numbers in both arms and inevitable stochastic 414 
events in the latter years of the study. A different cyclical pattern of VL between control and 415 
intervention villages is unlikely to have occurred due to the randomization of trial clusters.  416 
 417 
Clinical VL cases continued to be notified in villages during the years of collar use, 418 
indicating that collars were not wholly effective in interrupting transmission. Villages with 419 
higher pre–intervention incidence were more likely to experience continued transmission, 420 
despite achieving greater relative reductions in disease incidence compared to villages of low 421 
pre–intervention incidence. This raises the possibility that the collar coverage was insufficient 422 
in some villages.  423 
 424 
Collar coverage showed significant variation between villages with some being consistently 425 
low. Changes in village VL incidence was not associated with village coverage, nor indeed 426 
with any demographic variable. In three of the seven collared villages where the intervention 427 
failed to prevent a higher number of incident cases compared to controls, annual collar 428 
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coverage was >84% (average c.90%); and in all accept one of the 7 villages, the minimum 429 
annual coverage was >77%. Therefore, we do not the attribute these failures to lower collar 430 
coverage levels. Nor do we attribute it to collar losses or to non–compliance (owner refusing 431 
to have collars fitted to dogs). Short–term allergic dermal reactions to deltamethrin, reported 432 
in 2%–16% of collared dogs in two Brazilian studies[32, 37], usually causes owners to 433 
remove the collars. Such adverse effects were not reported in this trial, nor in the previous 434 
trial in NW Iran[31]. Similarly, there were no cases of dog owners refusing to have collars 435 
fitted to their dogs by the Health Promoters. 436 
 437 
Dogs ≤3m old were not collared (following label instructions) but represented <3% of the 438 
canine population.  The period of latency to infectious onset far exceeds the 4 month 439 
transmission season[6], thus ruling out these dogs as significant reservoirs for continued 440 
transmission. Stray dogs were rarely seen (27 in total), equivalent to <0·2 dogs per study 441 
village year. Although local wild canid populations can support infections (Mohebali 2016), 442 
their densities are relatively low, and the role of wild canids in maintaining transmission is 443 
disputed[8, 52, 53]. 444 
 445 
Potential scale-up and sustainability 446 
A significant finding of this study was that the intervention effect was achieved under the 447 
operational conditions as implemented by the DTARH VL control program. After ensuring 448 
that the design and village randomisation processes met CRT analytical requirements, the 449 
authors had minimal contact with authorities. The authors supplied known numbers of collars 450 
to the DHCs who distributed them to the villages, and collated details of the collar 451 
implementation. This provided the opportunity to measure the logistics and likely 452 
sustainability of programmatic scale–up.  453 
 454 
Collars were fitted within only 15 days of village supply, and collar losses were rapidly 455 
replaced, suggesting coverage levels were maintained during the transmission seasons. 456 
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Neither coverage level nor time to complete collar fitting were related to the total number of 457 
dogs eligible for a collar, concluding that lower village coverage levels were not due to time 458 
constraints. Feasibility of a regional–level scale–up was indicated by DTARH taking only 16 459 
days to deliver collars to all 40 villages spread over an area of 15,000km2, and total collars 460 
being fitted within one month from collar provision to the first village.  461 
 462 
Collars were socially accepted, visibly distinguished treated dogs, and should not require 463 
replacement every 3–4 weeks, unlike alternative topical formulations. Coupled with the short 464 
transmission season, effective collar duration, and rapid replacement rate, the feasibility of 465 
effective sustainable scale–up is indicated. Collar losses in this region of between 1% per 466 
month[31] and 1.7% (95% CI: 1.6%, 1.9%) per month (this study), were not substantially 467 
higher than in other endemic regions: 0·8% in Brazil[37] and 0·6–0·7% in Italy[34, 54], 468 
though exceptional rates, 7·8% and 8·2%, in both continents have been reported[32, 33].  469 
 470 
Sustainability will be governed also by costs and cost–effectiveness. Considering the cost of 471 
collars alone, in this study, collars were donated by the manufacturer. However, based on €14 472 
per collar, the annual material cost would have equated to approximately €24,000, or €96,000 473 
over 4 years. That is €4,364 per VL case averted compared to case numbers in the control 474 
arm. This value is for a period with 70% relative decline in reported case numbers from the 475 
late 1990s to 2014[9]. Better cost–effectiveness may be expected as the cyclical waning in 476 
case numbers inevitably reverses in non–intervention regions.  477 
 478 
One key knowledge gap is how best to implement dog collar programs: currently unknown is 479 
the minimum community coverage level necessary to reduce transmission, equivalent to 480 
vaccination coverage thresholds calculated to maintain herd immunity[55]. Mathematical 481 
models suggest that increasing collar coverage from 70% to 90% could cause moderate to 482 
substantial reductions in both canine and human infection prevalences[32, 56, 57]. However, 483 
three empirical studies that report coverage of 70%–100% failed to corroborate these 484 
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predictions[31, 34, 37]. Without known target thresholds, collar campaigns may result only in 485 
protection of the individual dog or its household. 486 
 487 
Of relevance to NTD elimination strategies, our data suggest that greater initial reductions in 488 
incidence may be achieved in communities with higher compared to lower preexisting 489 
transmission pressure. One prediction is that by reducing transmission, infection in the lower-490 
prevalence settings becomes more clustered, thus more stable and more resilient to 491 
interventions[58]. Approaching elimination will require different control strategies to those 492 
used in the initial attack phase. For example, heterogeneities in household sand fly densities, 493 
and the transmission potential of individual vectors and reservoirs[53, 59, 60], imply the need 494 
for high coverage levels to encounter such transmission hotspots. 495 
 496 
In conclusion, the results of this study promote the community-wide application of 497 
insecticide–impregnated collars as a public health tool to reduce clinical VL burdens, not just 498 
human and canine infection. The observed level of impact was achieved working within the 499 
existing MoH infrastructure, demonstrating many desirable attributes of a potentially 500 
sustainable control program that could be scaled–up with minimal additional technical 501 
capacity training.  502 
 503 
Supporting Supplementary Information  504 
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Figure legends 514 
Figure 1. Trial design 515 
 516 
Figure 2. Confirmed VL case incidence during the 1998 to 2005 transmission seasons in 517 
collar villages (black line, N=40) and control villages (red line, N=40). Arrow represents 518 
when collars were fitted in late June/early July of each year before the start of transmission. 519 
 520 
Figure 3. Frequency distribution of the absolute differences in post–intervention VL case 521 
incidence per 1000 between the 40 pair–matched collar and control villages. Negative 522 
differences represent a reduction in incidence attributed to the collar intervention. Positive 523 
changes represent an increase in incidence in the collar compared to the pair–matched control 524 
village. Values calculated as (post incidence collar– control) for pair–matched villages. 525 
 526 
Figure 4. The absolute differences in the post–intervention period VL case incidence per 527 
1000 between the pair–matched collar and control villages. Villages were pair–matched 528 
based on their pre–intervention incidence as described in the Methods, and ordered from low 529 
to high (Y axis: numbers 1–40). Dashed line: least squares linear fit from regression of the 530 
post–intervention incidence difference against the pre–intervention incidence. 531 
 532 
Figure 5. Association between the pre– and post–intervention incidence per 1000 in the 40 533 
control and 40 collar villages. Line: least squares linear fit from regression of the post–534 
intervention incidence against the pre–intervention incidence, weighted by number of 535 
children in the denominator (symbol size). 536 
 537 
Figure 6. Association between the intervention effect on pair–matched collar and control 538 
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village incidence per 1000 and the village annual collar coverage level (circles). Y axis error 539 
bars represent the minimum and maximum annual dog collar coverage per village over the 4 540 
years intervention. 541 
 542 
 543 
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